Rapid development of severe interstitial pneumonia caused by epoprostenol in a patient with primary pulmonary hypertension.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15385376.
- Also identified by DOI 10.1213/01.ANE.0000130615.28893.52.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A young woman with primary pulmonary hypertension developed severe interstitial pneumonia (IP) 5 days after induction of epoprostenol infusion. Although the pathogen involved was not identified, her IP was initially responsive to steroids, and discontinuation of steroid therapy caused the redevelopment of IP. After intensive treatment, including steroid therapy and inhaled nitric oxide, epoprostenol was successfully switched to prostaglandin E(1) infusion and she recovered. Epoprostenol infusion can cause a rapid severe IP, even soon after the induction of therapy. Clinicians should keep this syndrome in mind, especially when treating a severe case of IP.
Medical subject headings
- Epoprostenol
- Hypertension, Pulmonary
- Lung Diseases, Interstitial
- Platelet Aggregation Inhibitors